Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboure...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvala, Heli, Mehew, Jennifer, Robb, Matthew L, Ijaz, Samreen, Dicks, Steven, Patel, Monika, Watkins, Nicholas, Simmonds, Peter, Brooks, Tim, Johnson, Rachel, Gopal, Robin, Roberts, David J, Zambon, Maria, Thomas, Stephen, MacLennan, Sheila, Estcourt, Lise, Brailsford, Su, Baklan, Hatice, Tettmar, Kate, Kellington, Jeremy, Sell, Joanne, Miflin, Gail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376844/
https://www.ncbi.nlm.nih.gov/pubmed/32700670
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.28.2001260
Descripción
Sumario:Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Ejemplares similares